Macular Disease Foundation Australia has launched Eye Connect, the first comprehensive community service that offers people living with Australia’s leading cause of blindness access

Patients who take semaglutide (Ozempic, Wegovy) for type 2 diabetes or obesity could potentially be at risk for nonarteritic anterior ischemic optic neuropathy (NAION),

The ranibizumab ocular implant (Susvimo) for neovascular age-related macular degeneration (nAMD) will return to the US market shortly after a voluntary hiatus of almost

The United States Food and Drug Administration (FDA) has approved FYB203/Ahzantive (aflibercept-mrbb), a biosimilar to Eylea developed by Formycon.